Detalhe da pesquisa
1.
Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.
N Engl J Med
; 390(17): 1560-1571, 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38587254
2.
Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Five Years.
N Engl J Med
; 389(21): 1949-1960, 2023 Nov 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37874020
3.
Safety and Efficacy of Ticagrelor Monotherapy in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: An Individual Patient Data Meta-Analysis of TWILIGHT and TICO Randomized Trials.
Circulation
; 149(8): 574-584, 2024 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37870970
4.
Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement.
N Engl J Med
; 387(14): 1253-1263, 2022 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36121045
5.
Polypill Strategy in Secondary Cardiovascular Prevention.
N Engl J Med
; 387(11): 967-977, 2022 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36018037
6.
Invasive vs. conservative management of older patients with non-ST-elevation acute coronary syndrome: individual patient data meta-analysis.
Eur Heart J
; 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38596853
7.
Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure.
Circulation
; 148(13): 1011-1022, 2023 09 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37621153
8.
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
N Engl J Med
; 385(16): 1451-1461, 2021 10 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34449189
9.
Ticagrelor with or without aspirin following percutaneous coronary intervention in high-risk patients with concomitant peripheral artery disease: A subgroup analysis of the TWILIGHT randomized clinical trial.
Am Heart J
; 272: 11-22, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38458371
10.
Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR-Pooled analysis.
Diabetes Obes Metab
; 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38558314
11.
Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
Eur Heart J
; 44(5): 396-407, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36478225
12.
Rapid, accurate publication and dissemination of clinical trial results: benefits and challenges.
Eur Heart J
; 44(40): 4220-4229, 2023 Oct 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37165687
13.
Socioeconomic Deprivation: An Important, Largely Unrecognized Risk Factor in Primary Prevention of Cardiovascular Disease.
Circulation
; 146(3): 240-248, 2022 07 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35748241
14.
Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes.
Circulation
; 146(9): 676-686, 2022 08 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35762322
15.
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
Circulation
; 145(3): 184-193, 2022 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34779658
16.
Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction.
Circulation
; 146(14): 1046-1055, 2022 10 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36098051
17.
Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial.
Lancet
; 399(10333): 1401-1410, 2022 04 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35390320
18.
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
N Engl J Med
; 383(15): 1413-1424, 2020 10 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32865377
19.
Impact of standard modifiable cardiovascular risk factors on 2-year all-cause mortality: Insights from an international cohort of 23,489 patients with acute coronary syndrome.
Am Heart J
; 264: 20-30, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37279841
20.
Fatal, ischemic and bleeding risk of patients meeting the selection criteria of the TWILIGHT trial: Insights from a large PCI registry.
Am Heart J
; 263: 26-34, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37094668